CD28 and neoplasm: Previous studies have shown that the P28BBz receptor, containing signaling domains of CD28, 4-1BB, and CD3zeta, outperforms receptors with only one or two of these domains in vivo, enhancing T-cell survival, cytokine release, and tumor-killing ability [155].